Page 10 - DIAGEN-EN

Hematology primeFISH Products

HEMATOLOGY
PANEL

17-091 EVI1 (3q26.2) Breakapart

Inv(3)/t(3;3) and less commonly inv(3;3) chemotherapy and poor clinical outcome.
(q26.2;q21q26.2) occur in 1-2.5% of acute myeloid Chromosomal rearrangements involving the 3q26.2
leukemia (AML) and occur in myelodysplastic region are associated with myeloid malignancies,
syndromes and chronic it is alsa observed in the abnormal expression of the MECOM gene, an
blastic stage of myeloid leukemia. Various other unfavorable prognosis, and an aggressive clinical
MECOM translocations involving other fusion partner course.
genes have alsa been reported in various types of
myeloid malig nancies. 3q26.2 rearrangements are
associated with minimal or no response to

INVERTION

WI-4113 RH58597 SHGC-9113 SHGC-81191 D11S3226 RH78696
5' 3' 5' 3' 3' 5'
Cent Tel NORMAL
GOLIM4 MECOM MYNN

470 kb 164 kb 234 kb

RED SEPERATED BLUE SEPERATED

t(3;3)(q21;q26.2) Inv(3)

3q26.2

(Not to scale)

www.diagen.com.tr References
Arber DA, et al. (2016) Blood 127: 2391-405.
De Braekeleer E, et al. (2011) Anticancer Res 31: 3441-8.
Swerdlow et al., (eds,) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, Lyon, France, 4th edition, IARC,2017
Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines:
fluorescence in situ hybridization. Genet Med. 2011;13(7):667-675.

10 PRODUCT CATALOGUE